An Anatomico-Clinical Overview - Advances in Clinical ...
An Anatomico-Clinical Overview - Advances in Clinical ...
An Anatomico-Clinical Overview - Advances in Clinical ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Dr. Alois Alzheimer<br />
Before Him,<br />
The Disease Didn’t Have A Name<br />
Before Aricept,<br />
It Didn’t Have A Realistic Treatment<br />
donepezil hydrochloride<br />
Cont<strong>in</strong>u<strong>in</strong>g Commitment To Alzheimer’s<br />
ABBREVIATED PRESCRIBING INFORMATION<br />
ARICEPT ® (donepezil hydrochloride)<br />
Please refer to the SmPC before prescrib<strong>in</strong>g ARICEPT 5 mg or ARICEPT<br />
10 mg. Indication: Symptomatic treatment of mild to moderately<br />
severe Alzheimer's dementia.Dose and adm<strong>in</strong>istration: Adults/elderly;<br />
5 mg daily which may be <strong>in</strong>creased to 10 mg once daily after at<br />
least one month. No dose adjustment necessary for patients with<br />
renal impairment. Dose escalation, accord<strong>in</strong>g to tolerability, should<br />
be performed <strong>in</strong> patients with mild to moderate hepatic impairment.<br />
Children; Not recommended. Contra-Indications: Pregnancy.<br />
Hypersensitivity to donepezil, piperid<strong>in</strong>e derivatives or any excipients<br />
used <strong>in</strong> ARICEPT. Lactation: Excretion <strong>in</strong>to breast milk unknown.<br />
Women on donepezil should not breast feed. Warn<strong>in</strong>gs and<br />
Precautions: Initiation and supervision by a physician with experience<br />
of Alzheimer's dementia. A caregiver should be available to monitor<br />
compliance. Regular monitor<strong>in</strong>g to ensure cont<strong>in</strong>ued therapeutic<br />
benefit, consider discont<strong>in</strong>uation when evidence of a therapeutic effect<br />
ceases. Exaggeration of succ<strong>in</strong>ylchol<strong>in</strong>e-type muscle relaxation. Avoid<br />
concurrent use of antichol<strong>in</strong>esterases, chol<strong>in</strong>ergic agonists, chol<strong>in</strong>ergic<br />
antagonists. Possibility of vagotonic effect on the heart which may<br />
be particularly important with “sick s<strong>in</strong>us syndrome”, and<br />
supraventricular conduction conditions. There have been reports of<br />
syncope and seizures - <strong>in</strong> such patients the possibility of heart block<br />
or long s<strong>in</strong>usal pauses should be considered. Careful monitor<strong>in</strong>g of<br />
patients at risk of ulcer disease <strong>in</strong>clud<strong>in</strong>g those receiv<strong>in</strong>g NSAIDs.<br />
Chol<strong>in</strong>omimetics may cause bladder outflow obstruction. Seizures<br />
occur <strong>in</strong> Alzheimer's disease and chol<strong>in</strong>omimetics have the potential<br />
to cause seizures and they may also have the potential to exacerbate<br />
or <strong>in</strong>duce extrapyramidal symptoms. Care <strong>in</strong> patients suffer<strong>in</strong>g<br />
asthma and obstructive pulmonary disease. As with all Alzheimer’s<br />
patients, rout<strong>in</strong>e evaluation of ability to drive/operate mach<strong>in</strong>ery. No<br />
data available for patients with severe hepatic impairment. Drug<br />
Interactions: Experience of use with concomitant medications is<br />
limited, consider possibility of as yet unknown <strong>in</strong>teractions. Interaction<br />
possible with <strong>in</strong>hibitors or <strong>in</strong>ducers of Cytochrome P450; use such<br />
comb<strong>in</strong>ations with care. Possible synergistic activity with succ<strong>in</strong>ylchol<strong>in</strong>e<br />
-type muscle relaxants, beta-blockers, chol<strong>in</strong>ergic or antichol<strong>in</strong>ergic<br />
agents. Side effects: Most commonly diarrhoea, muscle cramps,<br />
fatigue, nausea, vomit<strong>in</strong>g, and <strong>in</strong>somnia. Common effects (>1/100,<br />
1/1,000, 1/10,000,